New scientific research in this field, including genetic and inflammatory studies in the treatment of wet macular degeneration, indicate that co-inhibiting Ang-2 and VEGF pathways leads to a significant reduction in blood vessel leakage and tumor-associated angiogenesis, offering a synergistic benefit over single-agent therapy [23]. The gene discussed is ANGPT2; the disease is age-related macular degeneration.